MAVALON THERAPEUTICS LTD has a total of 15 patent applications. Its first patent ever was published in 2016. It filed its patents most often in Brazil, Canada and China. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are ARAXES PHARMA LLC, Inthera Bioscience AG and VIIV HEALTHCARE UK LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Brazil | 2 | |
#2 | Canada | 2 | |
#3 | China | 2 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | Republic of Korea | 2 | |
#6 | United States | 2 | |
#7 | WIPO (World Intellectual Property Organization) | 2 | |
#8 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Heterocyclic compounds | |
#3 | Therapeutic chemical compounds | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Schann Stephan | 12 |
#2 | Manteau Baptiste | 12 |
#3 | Mayer Stanislas | 12 |
#4 | Catelain Thomas | 6 |
#5 | Dorange Ismet | 6 |
#6 | Blayo Anne-Laure | 5 |
#7 | Genet Cédric | 3 |
#8 | Genet Cedric | 3 |
#9 | Baptiste Manteau | 2 |
#10 | Stanislas Mayer | 2 |
Publication | Filing date | Title |
---|---|---|
KR20200035234A | Substituted heterocyclic compounds as allosteric modulators of Group II metabolic glutamate receptors | |
CN108834415A | The substituted tricyclic 1,4- benzodiazepine * ketone derivatives of allosteric modulators as II group metabotropic glutamate receptor |